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To elucidate the mechanisms underlying peripheral neuropathic pain in the context of HIV infection and
antiretroviral therapy, we measured gene expression in dorsal root ganglia (DRG) of rats subjected to sys-
temic treatment with the anti-retroviral agent, ddC (Zalcitabine) and concomitant delivery of HIV-gp120
to the rat sciatic nerve. L4 and L5 DRGs were collected at day 14 (time of peak behavioural change) and
changes in gene expression were measured using Affymetrix whole genome rat arrays. Conventional
analysis of this data set and Gene Set Enrichment Analysis (GSEA) was performed to discover biological
processes altered in this model. Transcripts associated with G protein coupled receptor signalling and cell
adhesion were enriched in the treated animals, while ribosomal proteins and proteasome pathways were
associated with gene down-regulation. To identify genes that are directly relevant to neuropathic
mechanical hypersensitivity, as opposed to epiphenomena associated with other aspects of the response
to a sciatic nerve lesion, we compared the gp120 + ddC-evoked gene expression with that observed in a
model of traumatic neuropathic pain (L5 spinal nerve transection), where hypersensitivity to a static
mechanical stimulus is also observed. We identiﬁed 39 genes/expressed sequence tags that are differen-
tially expressed in the same direction in both models. Most of these have not previously been implicated
in mechanical hypersensitivity and may represent novel targets for therapeutic intervention. As an exter-
nal control, the RNA expression of three genes was examined by RT-PCR, while the protein levels of two
were studied using western blot analysis.
 2008 European Federation of Chapters of the International Association for the Study of Pain. Published
by Elsevier Ltd. All rights reserved.1. Introduction
Peripheral nerve disorders are frequent complications of HIV
disease. Distal symmetrical polyneuropathy (DSP) is the most com-
mon peripheral nerve disorder associated with HIV (Verma et al.,
2005). About 40% of ambulatory HIV patients in the developed
world population have peripheral neuropathy, a prevalence which
has not altered with the advent of antiretroviral therapy (Smythapters of the International Associa
x: +44 20 8237 5109.et al., 2007). Of these 74–93% have pain, which is severe in 37–
43% of patients. In addition, 52% of people living with advanced
HIV have peripheral neuropathy associated with symptoms such
as pain (Simpson et al., 2006). The most common clinical features
of DSP are measurable sensory abnormalities, most noticeably loss
of sensitivity to thermal stimuli (Martin et al., 2003) and on-going,
paroxysmal or stimulus evoked pain (Dalakas and Pezeshkpour,
1988; Martin et al., 1999). There are two predominant (and clini-
cally similar) settings in which painful DSP may occur in HIV dis-
ease. First, a disease-related DSP associated with HIV disease,
likely involving virally mediated mechanisms such as the interac-
tion of the coat protein, gp120, with sensory neurones precipitat-
ing chemokine mediated neuronal damage (Oh et al., 2001;tion for the Study of Pain. Published by Elsevier Ltd. All rights reserved.
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second a drug-induced DSP, particularly associated with the use of
nucleoside reverse transcriptase inhibitors as part of an anti-retro-
viral therapy (Cherry et al., 2003; Cherry et al., 2006; Wallace et al.,
2007b).
We have characterized a model of HIV-related neuropathy,
termed gp120 + ddC (Wallace et al., 2007b), which combines peri-
neural administration of the HIV-1 coat protein, glycoprotein 120
(gp120), with systemic treatment with the nucleoside reverse
transcriptase inhibitor, 20,30-dideoxycytidine (ddC/Zalcitabine).
Gp120 + ddC treatment is associated with development of hyper-
sensitivity to static punctate mechanical stimuli, without hyper-
sensitivity to heat or cold, and thigmotaxis (anxiety-like
behaviour) (Wallace et al., 2007b). This model represents one clin-
ical scenario of DSP in the HIV patient treated with nucleoside re-
verse transcriptase inhibitors, whereby the sensory neurones are
damaged by a combination of gp120 and ddC effects (Cherry
et al., 2003). In this study, the gp120 + ddC model is used to eluci-
date the pathophysiology of DSP using gene microarrays of dorsal
root ganglions.
To distinguish between genes that are directly related to the
sensory dysfunction observed in the gp120 + ddC model and
those that are related to other aspects of the pathophysiological
response to a nerve lesion, we compared the gp120 + ddC-
evoked gene expression with that measured in a model of trau-
matic neuropathic pain, the L5 spinal nerve transection model
(L5 SNT), where hypersensitivity to a static mechanical stimulus
is also observed. This is a well established and commonly em-
ployed model of peripheral nerve lesion in rats and results in
hypersensitivity to mechanical, cold and heat stimuli. (Kim and
Chung, 1992; Choi et al., 1994; Ringkamp et al., 1999; Bridges
et al., 2001). Variants on this model have been utilized in previ-
ous microarray investigations (Wang et al., 2002; Valder et al.,
2003; Lacroix-Fralish et al., 2006; Levin et al., 2007) making this
an appropriate comparator model for this study. By comparing
gene expression proﬁles in these two distinct models, we aim
to highlight genes associated with HIV-related neuropathy as
well as mechanical hypersensitivity in neuropathic pain condi-
tions in general.2. Methods
2.1. Animals
All experiments conformed to the British Home Ofﬁce Regula-
tions and IASP guidelines (Zimmermann, 1983). Male Wistar rats
weighing 200-250 g at baseline were used for all experiments
(B&K, Hull, UK) and were housed in a temperature-controlled envi-
ronment, maintained on a 14:10 h light–dark cycle (experiments
were performed during the light phase) and provided with feed
and water ad libitum.
2.2. Experimental animals
2.2.1. Spinal nerve transection model (SNT)
Surgery was performed under general anaesthesia (1–2% isoﬂu-
rane in 1% O2 and 1% N20), using standard aseptic techniques. SNT
(n = 12) surgery was performed as previously described (Bridges
et al., 2001). Using the transverse processes of L6 as a guide, the left
paraspinal muscles were exposed and separated from the spinous
processes. The L6 transverse process was then removed by hemi-
laminectomy and the L5 spinal nerve exposed, ligated tightly with
a 3–0 silk suture, and cut 1 ± 2 mm distal to the suture. Sham
surgery (n = 12) was performed by exposing the L5 spinal nerve
as described above, but not damaging it.2.2.2. Gp120 + ddC model
Rats in this model were treated as described by Wallace and
colleagues (2007b). In eight anaesthetized (1–2% isoﬂurane in 1%
O2 and 1% N20) rats the left sciatic nerve was exposed to gp120
by placing a 5 mm  2 mm piece of gel foam soaked in saline con-
taining 200 ng HIV-1 gp120-MN (>95% pure; Immunodiagnostics,
Bedford, MA, USA) in direct contact with the nerve, to form a pool
of protein solution around the nerve that is left in place for 30 min.
Following this, oxidized regenerated cellulose (Surgicell, Ethicon);
previously soaked until saturation in the same saline-gp120 solu-
tion, was wrapped loosely around the sciatic nerve 2-3 mm proxi-
mal to the trifurcation so as not to cause any nerve constriction and
left in situ. The nerve was gently manipulated back into place and
the muscle and skin incisions closed with 4/0 silk sutures. Animals
were injected on the day of surgery with ddC (Roche, Basel, Swit-
zerland; 50 mg/kg in saline, i.p.) and injected thereafter three
times per week. Fourteen days after the day of surgery animals
were sacriﬁced and DRG tissue was collected. Sham surgery
(n = 8) was performed by exposing the left sciatic nerve as de-
scribed above, but exposing it to 0.1% rat serum albumin. The sham
group also received saline as a control for ddC.
2.2.3. Varicella Zoster Virus (VZV) infection model
We used an additional model of neuropathic pain, the VZV
infection model, for validation of the differential expression of
three of our candidate genes by RT-PCR and immunoblot analysis.
Rats in this model were treated as previously described by Hasnie
and colleagues (2007). In brief, VZV (strain Dumas) was propagated
on ﬁbroblast (primary human embryonic lung) cells and harvested
when cells exhibited 80% cytopathic effect (cpe) (equivalent to
104–105 plaque forming units). Animals (n = 16) were subcutane-
ously injected with 50 ll viral inoculum into the mid-plantar gla-
brous footpad of the left hind limb. Control animals (n = 16)
received similar injection of uninfected ﬁbroblast cells. Fourteen
days after the injection, animals were sacriﬁced and L4 and L5
DRG tissue was harvested.
2.3. Behavioural reﬂex testing
Punctate mechanical hypersensitivity was assessed using
graded ‘‘von Frey” nylon ﬁlaments (Alan Ainsworth, UCL, London),
which were used to deliver a calibrated indentation pressure
against the hairless skin of the hind paws. The withdrawal thresh-
old was determined by sequentially increasing and decreasing the
stimulus strength and threshold response was deﬁned by the nom-
inal bending force of the ﬁlament that evoked foot withdrawal at
least three times in every ﬁve applications when delivered at a rate
of 1 Hz (Chaplan et al., 1994). Baseline measurements were ob-
tained for all animals on two separate occasions within the week
prior to surgery. Following surgery, behavioural reﬂex tests were
carried out in a blinded manner. Animals were re-tested on day
14 post-surgery/infection and only animals demonstrating a signif-
icant (paired t-test, p < 0.05) reduction in ipsilateral PWT com-
pared to baseline values were retained for microarray analysis.
2.4. Tissue collection and microarray
Animals were sacriﬁced by administration of an overdose of
pentobarbitone (100 mg/kg Animalcare Ltd., York, UK). Ipsilateral
DRG from lumbar segments L4 and L5 were dissected on ice, and
snap frozen in liquid nitrogen. Transection of the L5 spinal nerve
in the SNT model was conﬁrmed on post-mortem and only these
animals were included in the microarray analysis. Prior to RNA
preparation, for the gp120 + ddC model, ipsilateral L4 and L5 DRGs
from two animals were pooled, to provide enough tissue for RNA
preparation. For the SNT model, only ipsilateral L5 DRGs from three
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were prepared. Total RNA was extracted using TRIzol reagent
(Invitrogen, Carlsband, CA, USA), and further puriﬁed using an
RNeasy Mini kit (Qiagen, Crawley, UK), according to the manufac-
turer protocols. Affymetrix GeneChip Rat Genome 230 2.0 arrays
(Santa Clara, CA, USA) that study over 30,000 transcripts and vari-
ants from over 28,000 well-substantiated rat genes, were used for
these experiments. Biotin labeled cRNA was generated using the
Affymetrix Small Sample Labeling Protocol vII (http://
www.affymetrix.com). Approximately 200 ng total starting RNA
was used for each sample. Labeled cRNA fragmentation, as well
as array hybridization, washing, and staining were performed as
described in the Affymetrix GeneChip Expression Analysis Tech-
nical Manual (http://www.affymetrix.com).
2.5. Data analyses
CEL ﬁles were obtained with Affymetrix Microarray Suite soft-
ware. Data was analysed using R v2.3.1 and Bioconductor v1.8
packages (Gentleman et al., 2004) as follows: Quality control tests
and RMA data normalization were performed using Simpleaffy
(Wilson and Miller, 2005) and Affy (Gautier et al., 2004). The nor-
malized data was ﬁltered, using Geneﬁlter (http://www.biocon-
ductor.org/packages/1.8/bioc/html/geneﬁlter.html), to remove
probe sets with minimal expression levels (i.e., probe sets failing
to have a signal higher than log2(100) in three or more arrays). Sta-
tistical analysis was performed using linear models and empirical
Bayes methods implemented in the Limma package (Smyth,
2004; Smyth, 2005). Benjamini and Hochberg’s step-up method
(Reiner et al., 2003) with false discovery rate (FDR) less than 0.1
was used to control for multiple testing. The threshold p value con-
sistent with an FDR near 10% was identiﬁed as 0.03 for the SNT
model (10.4% FDR) and 0.004 for the gp120 + ddC model (9.6%
FDR). The lists of statistically signiﬁcant genes were loaded into
GeneSpring GX (v7.3.1) software (Agilent Technologies, Cheshire,
UK), where a second ﬁlter (fold difference less than 1.2-fold) was
applied to further reduce false positive results (Bakay et al.,
2002). We chose 1.2-fold change, which is a moderate cut-off, to
signify differential expression, because the two cycle ampliﬁcation
protocol used in this study is thought to suppress fold differences
(see discussion). Finally, Venn diagrams were used to cross-com-
pare data between models. The microarray data is available in
MIAME-compliant (minimum information about a microarray
experiment) format at the ArrayExpress database (http://www.e-
bi.ac.uk/arrayexpress) (Parkinson et al., 2007) under accession
codes E-MEXP-974, E-MEXP-976.
2.5.1. Functional association analysis
Associations with the annotations of the Gene Ontology (GO)
Consortium (Ashburner et al., 2000) were obtained, for the lists
of signiﬁcant probe sets (10% FDR and over 1.2-fold difference) that
correspond to each model, using MAPPFinder 2.0, a part of the Gen-
MAPP 2.1 application package (Dahlquist et al., 2002; Doniger
et al., 2003). To ease the interpretation of results, output data were
manually ﬁltered, using criteria used by Doniger and colleaguesTable 1
Primer sequences used for RT-PCR
Gene name 50 primer
TrkB_FL TCTATGAAGACTGGACCACGC
TrkB_T1 TCTATGAAGACTGGACCACGC
TrkB_T2 TCTATGAAGACTGGACCACGC
Npy ACTGACCCTCGCTCTATCCC
Pap/Reg2 TGGCCTTCCCAGTCATGTC
Vgf TACCCAGAACGAGGATTGCG
PpiA ACCCCACCGTGTTCTTCGAC(2003), to remove terms that represented the same genes (typically
parent–child processes). For a process to be included in the results,
it was required that the z score from the MAPPFinder statistics was
higher than 2, with a permute p value less than 0.01, and that at
least one gene changed signiﬁcantly for this node (local results).
Also, terms that (a) comprised of 5 or less genes; or (b) had more
than 200 genes changed (nested results) were removed, because
they were either too speciﬁc or too general for the data
interpretation.
Pathway analysis was also performed using Gene Set Enrich-
ment Analysis (GSEA) version 2.0 (Subramanian et al., 2005; Subr-
amanian et al., 2007). A total of 253 gene sets were applied. These
were obtained from the C2/Canonical Pathways collection of
MSigDB version 2.1 (Subramanian et al., 2005), which contains
gene sets collected from various sources such as online pathway
databases, publications in PubMed, and knowledge of domain ex-
perts. Fourteen additional gene sets were generated by querying
the Affymetrix NetAffx tool (https://www.affymetrix.com/analy-
sis/netaffx/index.affx) with pain related key words. GSEA was run
with default settings by using the gene_set permutation option
and performing 1000 gene permutations for the determination of
statistical signiﬁcance. Signiﬁcant FDR and p values were less than
25% and 0.01, respectively, in accordance with GSEA
recommendations.
2.6. RT PCR
RT-PCR was performed as previously described (Boucher et al.,
2000). The sequence of primers used is listed in Table 1. New pools
of DRG RNA from SNT-, gp120 + ddC- and VZV-treated animals
were used for these experiments. DRG RNA was extracted by using
guanidine isothiocyanate. Total RNA (2 lg) from L4 and/or L5 DRGs
of sham or treated animals (n = 3 per group) was treated with
DNase I, and cDNAwas synthesized with Superscript reverse trans-
criptase (Invitrogen, Paisley, UK) using random hexamers in a total
volume of 20 ll. In order to identify the optimal conditions for a
linear range of ampliﬁcation in the quantitative RT-PCR analysis,
the amount of each ampliﬁed product was ﬁrst checked at 24,
27, 30, 33, 36, and 39 cycles. Portions of the reverse-transcribed
solution (0.5 ll) of total RNA from treated or sham ganglia were
used for PCR. Each PCR (94 C, 30 s; 58 C, 30 s; 72 C, 1 min; 33 cy-
cles, 30 ll) was started with the primer pair speciﬁc for genes of
interest (see Table 1). The primer pairs for cyclophilin A (PpiA)
were added to the PCR reaction 5 cycles after the start. PCR prod-
ucts (10 ll) were visualized on 1.5% agarose gels, using ethidium
bromide. The intensity of each band was analysed using Image J
software (http://rsb.info.nih.gov/ij/) and normalized to cyclophilin
A. To test for differential expression, a Student’s t test with a signif-
icance level of p < 0.05 was used.
2.7. Western Blots
Protein extraction, SDS–PAGE, and Western blotting were per-
formed as previously described (Okuse et al., 1997). DRG were iso-
lated and snap frozen, and protein was extracted by30 primer Size (bp)
TTCTCCAAGCTCCCTCTTCAG 449
CCAGTCACAGCTCACAACAAG 422
AGTGGGCAAGGCTGAGTAATC 399
AACGACAACAAGGGAAATGG 400
AGATCTTGACAAGCTGCCACAG 445
CAACAGTACCGCGGCCAG 381
CATTTGCCATGGACAAGATG 300
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NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 1 mM PMSF,
1 lg/ml each aprotinin, leupeptin, pepstatin) followed by centrifu-
gation at 10,000 g for 10 min. The protein concentration of the
supernatant was determined by Bradford assay, and 50 lg protein
was applied to each lane of 12% SDS–PAGE. Wet transfer was per-
formed using Hybond ECL (Amersham), and the membrane was
blocked for 60 min in 5% non-fat dried milk in TBS-T (50 mM
Tris-HCl, pH 7.6, 140 mM NaCl, 0.1% Tween 20). The blot was
probed with goat anti-Reg2/Pap (1:1000 dilution, R&D systems),
rabbit anti-Atf3 (1:500 dilution, Santa Cruz Biotechnology) and
anti-Actin (1:5000, Sigma) antibodies. Results were visualized with
horseradish peroxidase-coupled anti-goat or anti-rabbit immuno-
globulins (Dako) using ECL Western blotting detection system
(Amersham).
3. Results
3.1. Mechanical hypersensitivity data
At day 14 post-intervention, all animals displayed hypersensi-
tivity to a punctate mechanical stimulus, in the limb ipsilateral
to treatment (Fig. 1). This has been previously established to be
the time of maximal mechanical hypersensitivity in both models
(Dowdall et al., 2005; Wallace et al., 2007b). On average there
was an 80% reduction from baseline in gp120 + ddC-treated ani-
mals and a 75% reduction in SNT-treatment. Mechanical hypersen-
sitivity was not observed in the contralateral paws of the treated0
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Fig. 1. Paw withdrawal thresholds (PWT) to graded von Frey ﬁlaments at day 14 vs. base
two rats per replicate for B. *, Signiﬁcant paired t test with p < 0.05 for comparing day 1animals (data not shown), nor in the ipsilateral paws of sham
animals.
3.2. Model-speciﬁc differential expression of genes
The microarray experiment was conducted at one time point
post-injury (day 14) and consisted of two conditions per model
(treated animal versus sham) with four replicates per condition.
To test for outlying chips, a number of quality control tests were
carried out on the raw and RMA normalized data ﬁles (data not
shown), which resulted in the exclusion of one of the replicates
for the treated SNT animals.
We deﬁned differentially expressed genes using criteria of 10%
FDR and overall fold difference from sham >1.2 (see Section 2). Of
the approximately, 30,000 transcripts queried on the Affymetrix
GeneChip Rat Genome 230 2.0 array, 656 probe sets were signif-
icantly disregulated in the gp120 + ddC DRGs. Of those, 243 were
upregulated versus sham, whereas 413 were downregulated (sup-
plementary tables 1 and 2). In SNT DRG, 2696 probe sets were
upregulated versus sham and 2444 downregulated (supplemen-
tary tables 3 and 4). Moreover, considering fold changes alone,
while only 40 probe sets showed over 2-fold expression differences
between sham and treated animals in the gp120 + ddC model,
1593 probe sets showed over 2-fold difference in the SNT model.
We interpret this as a reﬂection of the moderate amount of nerve
damage induced in the sciatic nerve in the gp120 + ddC models,
which is in contrast to the extensive trauma inﬂicted in the SNT
model.1
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To verify the accuracy of the microarray results, we compared
our SNT model results with two published microarray datasets
describing differential gene expression (13 or 14 days after injury)
in the DRG of rats subjected to spinal nerve ligation (SNL) (Wang
et al., 2002; Valder et al., 2003). Our SNT model is a variation of
the SNL model and thus our data are comparable to the SNL data-
sets. Both previous studies used rat RG-U34A arrays that contain
8799 probe sets and published lists of differentially expressed
genes that show greater than 2-fold difference with p < 0.05. They
compared ipsilateral to contralateral pools of L4, L5, and L6 DRG.
Despite these analytical and methodological differences to our
study, the data are expected to show strong similarities. Wang
and colleagues (2002) identiﬁed 102 upregulated and 46 downreg-
ulated genes, while Valder and colleagues (2003) identiﬁed 98
upregulated and 113 downregulated genes. We merged these lists
and identiﬁed probe sets for a total of 195 genes in the Rat Genome
230 2.0 array that we employed in this study. Hundred and ﬁfty-
nine of these probe sets (81.5%) are signiﬁcant in our SNT dataset,
with p < 0.04 (FDR < 0.1) and over 1.2-fold difference in the same
direction as the previously reported studies. For a more detailed
breakdown of these results, see supplementary Table 5. The corre-
lation between the SNT results and published observations sub-
stantiates the accuracy of our data.
3.4. Gene Ontology results
We used MAPPFinder/GenMAPP and GSEA to perform a general
search for pathways associated with gp120 + ddC treatment. With
MAPPFinder/GenMAPP we found that 50% of the 243 signiﬁcantly
upregulated and 48% of the 413 downregulated genes in this model
are linked to a GO term. Eleven GO functional annotation terms are
over-represented in the upregulated gene list, neuropeptide signal-
ling being the most signiﬁcant (Table 2). Several other terms are
related to organ development (e.g., tube morphogenesis, axono-
genesis). Three GO terms are over-represented in the downregu-
lated gene list (Table 2). They are all related to chloride channel
activity (GABA-A receptor activity, chloride ion binding, chloride
channel activity).
The GSEA software was used to obtain a more detailed classiﬁ-
cation of the data into various affected pathways. GSEA considers
all of the genes in an experiment, not only those above an arbitrary
cut-off in terms of fold-change or signiﬁcance. When GSEA was ap-
plied to the gp120 + ddC dataset, 20 gene sets were found to be up-
regulated (FDR < 2.5 and p < 0.01) (Table 3). These include ﬁve gene
sets that involve calcium dependent signalling (G alpha q pathway,Table 2
Functional categories of genes highlighted by MAPPFinder for the gp120 + ddC model
GO name GO type No. of genes ch
Upregulated
Neuropeptide signalling P 4/29
Hyaluronic acid binding F 2/8
Homophilic cell adhesion P 4/35
Organ morphogenesis P 9/154
Sex differentiation P 3/25
Blood vessel morphogenesis P 6/83
Regulation of epithelial cell proliferation P 2/7
Electron carrier activity F 5/71
Tube morphogenesis P 4/36
Branching morphogenesis of a tube P 3/22
Axonogenesis P 5/68
Downregulated
GABA-A receptor activity F 3/8
Chloride ion binding F 3/17
Chloride channel activity F 3/18Wnt/Ca2+/cyclic GMP pathway, calcium regulation in cardiac cells
pathway, Pyk2 pathway and calcium homeostasis) and three cell
adhesion gene sets (cell adhesion molecule activity, Brentani cell
adhesion and GO cell adhesion). This is in agreement with the
MAPPFinder results. The upregulation enriched gene sets also in-
clude a list of pain related genes. The genes that contribute to
the high enrichment score for this gene set are illustrated in
Fig. 2. Twelve gene sets are downregulated in the gp120 + ddC
model (Table 4). They include a gene set of ribosomal proteins,
three gene sets related to proteasomes and two for RNA/DNA tran-
scriptome reactome genes.
In the SNT model data, 44% of the signiﬁcantly upregulated and
43% of the downregulated genes are linked to a GO term. As shown
in supplementary Table 6, the majority of biological process GO
terms identiﬁed as signiﬁcant in the list of upregulated genes are
linked to neuroinﬂammation and immune system activation, high-
lighting the presence of dramatic neuroinﬂammation in SNT DRG.
In contrast, multiple GO terms linked with ion transport (especially
potassium ion transport), cell–cell signalling and cell communica-
tion are identiﬁed as signiﬁcant in the list of downregulated genes.
The obtained results agree with Wang et al. (2002), and Valder
et al. (2003) and provide another level of validation of our experi-
mental results. The same pathways were also identiﬁed using GSEA
analysis (supplementary tables 7 and 8). Interestingly, the gene set
containing pain related genes is amongst those linked with down
regulation in the SNT model. A detailed breakdown of the genes
that contribute to the high enrichment score for this gene set are
illustrated in Fig. 2.
3.5. Model cross comparisons
To identify genes that are relevant to mechanical hypersensitiv-
ity, we compared the lists of differentially expressed genes in both
models, created using criteria of 10% FDR and overall >1.2-fold dif-
ference from sham, with Venn diagrams (see Fig. 3). We found 14
probe sets that are commonly upregulated in the DRGs of SNT and
gp120 + ddC treated animals (Table 5). Only one of these is an EST
of unknown function. The remaining probe sets correspond to
annotated genes which can be subdivided into four groups on
the basis of their function: signal peptides (Pap/Reg2, NpY, Scube1,
Vgf), ion/protein transporters (Atp2B4, Dlg5, Slc4a8), transcription
factors (Arnt2, Bptf, Irf7, Midn, Per2) and a cell differentiation mol-
ecule (Lama5) (Table 5).
Twenty-ﬁve probe sets corresponding to 24 genes or ESTs were
downregulated in the DRGs of SNT and gp120 + ddC treated ani-
mals (Table 6). Thirteen of these have unknown function while
the remaining eleven are implicated in a variety of processesanging/no. of genes measured in the array Z score Permute p
4.852 0
4.924 0.003
4.281 0.003
3.801 0.004
3.83 0.005
3.727 0.005
5.315 0.006
3.326 0.006
4.198 0.008
4.169 0.009
3.447 0.009
5.767 0
3.577 0.005
3.435 0.006
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392 K. Maratou et al. / European Journal of Pain 13 (2009) 387–398varying from metabolism (Gla, Fpgt, St8sia3), to ion/protein trans-
port (Efcbp1, Kif5a, Rab27b, Sv2b), transcriptional activation
(Esrrg), mitochondrial function (Senp5) axon guidance (Robo2)
and signal transduction (Nkiras1).
3.6. RT-PCR and immunoblotting results
We sought to conﬁrm the gene expression changes of a selected
subset of genes using semi-quantitative RT-PCR analysis. Cyclophi-
lin A was used as internal control.
First, we measured the truncated isoform of TrkB (TrkB.T1), a
receptor for BDNF (Huang and Reichardt, 2003) as this was the
most upregulated gene in the gp120 + ddC DRG (supplementary
information table 3). The Affymetrix GeneChip Rat Genome 230
2.0 array also contains a probe set (1368972_at) that corresponds
to the full length isoform of this gene (TrkB.FL). It showed no sig-
niﬁcant change in expression between treated and sham animals.
We designed primers speciﬁc for TrkB.FL, for TrkB.T1 as well as
for a second truncated isoform of TrkB (TrkB.T2) which is absent
from the microarray. Only TrkB.T1 was found to be up-regulated
in gp120 + ddC treated animals supporting the microarray ﬁndings
(Fig. 4).
We also measured levels of NpY, Pap/Reg2 and Vgf, the three
neuropeptides that are commonly upregulated in SNT and
gp120 + ddC models, by RT-PCR. All three genes were found to be
markedly upregulated in agreement with the microarray results
(Fig. 5). As a further test for the link between these genes and
mechanical hypersensitivity, we also measured the differential
expression of these three genes in L4 and L5 DRG of rats infected
with Varicella Zoster virus. This is a disparate animal model of neu-
ropathic pain, used to model the mechanisms underlying post-her-
petic neuralgia (Sadzot-Delvaux et al., 1990; Fleetwood-Walker
et al., 1999; Dalziel et al., 2004; Garry et al., 2005), which is also
associated with similar mechanical hypersensitivity and thigmo-
taxis behaviour as is observed in SNT and GP120 + ddC (Hasnie
et al., 2007; Wallace et al., 2007b). All three genes were also upreg-
ulated in the VZV treated animals (Fig. 5).
We further conﬁrmed the upregulation of PAP/Reg2 using
immunoblot analysis to test if the observed mRNA level changes
are maintained at the protein level. Pap/Reg2 was found to be
upregulated by 1.4-fold for gp120 + ddC, 1.4-fold for SNT and by
1.1-fold for VZV (Fig. 6) further validating our microarray results.
4. Discussion
To elucidate the mechanisms underlying HIV DSP pain, we per-
formed gene expression proﬁling in the L4 and L5 DRG of a recently
developed rat model (gp120 + ddC) (Wallace et al., 2007b). We
then focused our analysis towards the identiﬁcation of genes that
are directly relevant to presentation of mechanical hypersensitiv-
ity. To do so, we compared the gene proﬁle of the gp120 + ddC
model, with that of a model of direct sciatic nerve trauma (SNT)
that although based on a distinct aetiology, shares the common
outcome of mechanical hypersensitivity. As predicted, the models
are associated with distinct sets of gene expression changes. How-
ever, we identiﬁed 39 genes/ESTs that are differentially regulated
in the same direction in both models which may therefore underlie
the common link of mechanical hypersensitivity.
Gp120 and nucleoside analogues are thought to affect cells by a
variety of mechanisms including via cytokine and chemokine sig-
nalling pathways (Oh et al., 2001; Bhangoo et al., 2007). Accord-
ingly, many biological process pathways overrepresented in the
gp120 + ddC upregulated gene list involve signal transduction,
such as neuropeptide signalling and the G alpha q pathway. Upreg-
ulated genes associated with these terms include TrkB.T1, Penk1,
Celsr3, Nfkb2 and Itpr3. Interestingly, of these genes, the truncated
Fig. 2. Heat map of the genes contributing most to the high enrichment score of the pain gene set for (A) gp120 + ddC and (B) SNT. Genes are ranked according to their
expression under each experimental condition. For gp120 + ddC there is an association with upregulation, and thus the most differentially expressed genes are shown at the
top of the heat map. For SNT there is an association with downregulation and thus the most differentially expressed genes are shown at the bottom of the heat map.
Expression values are shown for each replicate within a condition and are represented as colours, where the range of colours (red, pink, light blue, dark blue) shows the range
of expression values (high, moderate, low, and lowest).
K. Maratou et al. / European Journal of Pain 13 (2009) 387–398 393isoform of TrkB (TrkB.T1), a receptor for BDNF (Huang and Reic-
hardt, 2003), is the most upregulated gene in the gp120 + ddC
model, which was further validated with RT-PCR. TrkB full length
isoform (TrkB.FL)-BDNF signalling has been shown to protect neu-
rons from gp120 induced cell death (Mocchetti and Bachis, 2004),but also thought to contribute to pain facilitation (Guo et al., 2006).
TrkB.T1 is thought to modify the action of full length TrkB (TrkB.FL)
signalling (Biffo et al., 1995; Eide et al., 1996; Haapasalo et al.,
2001) and thus it is an interesting candidate for the development
of hypersensitivity in the gp120 + ddC model.
Table 4
Gene sets associated with gene downregulation in gp120 + ddC using gene set enrichment analysis
Gene set name Top 5 genes Source Size NOM p-val FDR q-val
PROTEASOME_DEGRADATION Psmc6, Rps27a, Psma4, Psma1, H2afz Broad Institute 39 0 2.40e04
PROTEASOME Psma2, Psma4, Psma1, Psma5, Psmb1 GenMAPP 18 0 3.60e04
RIBOSOMAL_PROTEINS Rps24, Rps27a, Rps25, Rpl21, Rpl7 GenMAPP 86 0 7.21e04
STRIATED_MUSCLE_CONTRACTION Tpm1, Ttn, Tnnt1, Tnni1, Myl2 GenMAPP 39 0 0.003
PROTEASOMEPATHWAY Psma2, Psma4, Psma1, Psma5, Psmb1 BioCarta 22 0 0.02
ELECTRON_TRANSPORT_CHAIN Cox6a2, Cox17, Nduf5, Cox7b, Ndyfs4 Broad Institute 80 0 0.021
ROME_INSULIN_2F_UP Dpysl3, Ppp1r12a, Sh3glb1, Canx, Tpm1 Rome et al., J. Biol. Chem., 2003 204 0 0.161
DNA_REPLICATION_REACTOME Orc3l, Prim2a, Rfc1, Rps27a, Orc4l GenMAPP 34 0.002 0.075
OXIDATIVE_PHOSPHORYLATION Cox6a2, Ndufa5, Cox7b, Atp6v1d, Atp5o KEGG 48 0.003 0.066
RNA_TRANSCRIPTION_REACTOME Ccnh, Gtf2f2, Cdk7, Mnat1, Polr2g GenMAPP 28 0.009 0.115
PORPHYRIN_AND_CHLOROPHYLL_ METABOLISM Eprs, Blvra, Cp, Urod, Hmox1 GenMAPP 18 0.020 0.153
UBIQUITIN_MEDIATED_PROTEOLYSIS Ube2b, Ube2n, Ube2g1, Ube2d3 GenMAPP 20 0.022 0.1813
Top 5 genes – top 5 ranking genes belonging to a gene set; source – source for the gene set; size – number of genes in a gene set; NOM p-val – nominal p value; FDR q-val –
false discovery rate.
Fig. 3. Venn diagrams to cross-compare the lists of signiﬁcant probe sets (>1.2-fold
difference and 10% FDR) between the SNT and gp120 + ddC models. (A) comparison
of upregulated gene lists; (B) comparison of downregulated gene lists.
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2001; Keswani et al., 2003a), while gp120may cause axonal degen-
eration directly through activation of a mitochondrial caspase
pathway and indirectly through neuronal apoptosis mediated by
the activation of Schwann cells (Melli et al., 2006). GSEA analysis
identiﬁed a gene set of ribosomal proteins as signiﬁcantly associ-
ated with downregulation in the gp120 + ddC model. This set con-
tains genes like Rps24, Rps27a, Rps25, and Rpl7.
The mitochondrial dysfunction induced by ddC alters calcium
homeostasis in cultured DRG neurons (Werth et al., 1994) and in
a model of ddC-associated painful peripheral neuropathy (Joseph
et al., 2004). Gp120 is also associated with an increase in [Ca2+]i
in subsets of cultured DRG cells through the activation of chemo-
kines (Oh et al., 2001). Therefore, alterations in calcium activity
could underlie a synergistic effect of a combination of gp120 and
ddC exposure. Such synergism of the treatments is suggested by
the fact that behavioural indices of pain are enhanced in theTable 5
Probe sets upregulated for the SNT and gp120 + ddC models
Probe set ID Gene title
1373315_at Aryl hydrocarbon receptor nuclear translocator 2
1376911_at ATPase, Ca2+ transporting, plasma membrane 4 (homo sapiens) (pred
1376182_at Bromodomain PHD ﬁnger transcription factor (Mus) (predicted)
1377121_at Discs, large homolog 5 (Drosophila) (predicted)
1383564_at Interferon regulatory factor 7
1388932_at Laminin, alpha 5
1377103_at Midnolin (predicted)
1387154_at Neuropeptide Y
1368238_at Pancreatitis-associated protein
1368303_at Period homolog 2 (Drosophila)
1371910_at Signal peptide, CUB domain, EGF-like 1 (Mus) (predicted)
1392238_at Solute carrier family 4 (anion exchanger), member 8 (Mus) (predicte
1368359_a_at VGF nerve growth factor inducible
1393477_at –
–, Unknown.gp120 + ddC model as compared to either treatment alone (Wal-
lace et al., 2007b). We ﬁnd that several genes involved in calcium
ion transport (Casr, Plcg1 and Atp2a2) and calcium binding (e.g.,
Bcan, Egﬂ4, Dag1, Stat3, Capn1) are upregulated in the gp120 + ddC
model suggesting that changes in calcium regulation may contrib-
ute to the development of neuropathy and merit further
investigation.
Comparison of the gp120 + ddC and SNT model DRG gene
expression proﬁles indicates that the pathological processes inher-
ent to each model inﬂuence multiple gene expression pathways.
For example, pathways involved in signalling or cell–cell adhesion
are mainly downregulated in the SNT model and upregulated in
the gp120 + ddC model. Interestingly, certain genes implicated in
neuropathy formation and/or maintenance showed opposing pat-
terns of differential expression between models. For example; pro-
tein kinase C, epsilon (PKCe) and its signalling pathways have been
implicated in primary afferent nociceptor sensitization (Khasar
et al., 1999) and it is considered an important contributor to the
development of painful diabetic neuropathy (Ahlgren and Levine,
1994), taxol-induced painful peripheral neuropathy (Dina et al.,
2001b), painful alcoholic neuropathy (Dina et al., 2000; Dina
et al., 2006), and inﬂammatory hyperalgesia (Khasar et al., 1999;
Aley et al., 2000; Dina et al., 2001a; Parada et al., 2005). PKCe
was down regulated in SNT DRG and up-regulated in gp120 + ddC
DRG. The calcitonin-related polypeptide alpha (Calca) gene, that
codes for CGRP, which has been implicated in the development
of thermal hypersensitivity in mice (Mogil et al., 2005) and
mechanical hypersensitivity in a traumatic model of rat (Jang
et al., 2004). Calca was found to be downregulated in the SNT mod-
el, but showed no signiﬁcant changes in expression for theGene symbol Fold increase SNT Fold increase gp120 + ddc
Arnt2 1.4 1.3
icted) Atp2B4_predicted 2.9 1.3
Bptf_predicted 1.8 1.2
Dlg5_ predicted 1.5 1.2
Irf7 3.4 1.2
Lama5 1.8 1.3
Midn_ predicted 1.6 1.3
Npy 8.6 1.9
Pap/Reg2 22.3 1.2
Per2 2.6 1.3
Scube1_ predicted 1.6 1.4
d) Slc4a8_predicted 2.2 1.3
Vgf 3.5 1.3
– 5.0 1.5
Table 6
Probe sets downregulated for the SNT and gp120 + ddC models
Probe set ID Gene title Gene symbol Fold decrease SNT Fold decrease gp120 + ddc
1390892_at DEP domain containing 1B (predicted) Depdc1b_predicted 2.0 1.3
1386120_at Mus musculus EF hand calcium binding protein 1 (Mus musculus)
(predicted)
Efcbp1_predicted 1.7 1.4
1381445_at Estrogen-related receptor gamma Esrrg 2.5 1.4
1376753_at Fucose-1-phosphate guanylyltransferase Fpgt 1.7 1.3
1382063_at Galactosidase, alpha Gla 1.7 1.3
1382787_at Kinesin family member 5A Kif5a 2.0 1.7
1396215_at Similar to RIKEN cDNA 2610022G08 LOC502782 1.7 1.3
1396117_at Leucine zipper protein 2 (predicted) Luzp2_predicted 2.0 1.7
1397555_at Leucine zipper protein 2 (predicted) Luzp2_ predicted 1.4 2.0
1393847_at NFKB inhibitor interacting Ras-like protein 1 (predicted) Nkiras1_predicted 1.7 1.3
1370122_at RAB27B, member RAS oncogene family Rab27b 2.0 1.7
1393909_at Similar to KIAA1841 protein (predicted) RGD1305110_predicted 1.4 1.7
1382812_at Similar to Protein Njmu-R1 (predicted) RGD1310429_predicted 2.0 1.4
1378245_at Similar to 6430514L14Rik protein (predicted) RGD1311958_predicted 1.7 1.3
1382632_at Roundabout homolog 2 (Drosophila) Robo2 2.5 1.7
1382477_at SUMO/sentrin speciﬁc protease 5 (predicted) Senp5_predicted 1.4 1.4
1387435_at ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 St8sia3 1.4 1.3
1369627_at Synaptic vesicle glycoprotein 2b Sv2b 1.7 2.5
1394412_at Transmembrane protein 16C (predicted) Tmem16c_ predicted 3.3 1.4
1392045_at Transmembrane protein 22 Tmem22 2.0 1.3
1377917_at Transcribed locus – 1.7 1.4
1383162_at – – 1.3 1.4
1385972_at – – 1.4 1.4
1392663_at Transcribed locus – 1.7 1.3
1396676_at Transcribed locus – 2.7 1.4
–, Unknown.
Fig. 4. RT-PCR results for TrkB isoforms in gp120 + ddC treated animals. Normalized
expression levels for each isoform are expressed as ratios to cyclophilin. Data are
expressed as means ± SD. *, (p < 0.05) indicates statistical signiﬁcance between
treated and sham groups of animals (Student’s t test).
K. Maratou et al. / European Journal of Pain 13 (2009) 387–398 395gp120 + ddC model, which is in line with previous investigations
(Wallace et al., 2007b). This suggests that although these genes
have been deemed important in traumatic neuropathy, they may
not be associated with neuropathic pain of multiple pathophysio-
logical origins or the manifestation of mechanical hypersensitivity.
There are some limitations of our experimental approach which
require discussion. First, this study focuses on a single time point,
when mechanical hypersensitivity is well established. Thus the
genes identiﬁed are potentially important for this phase of
mechanical hypersensitivity. To fully identify candidate genes for
hypersensitivity generation and maintenance, this study would
have to be repeated at a number of time points, which is prohibi-
tively expensive given the current cost of this technology. Sec-
ondly, these microarray data reﬂects changes in gene expressionin the entire DRG, which is a heterogenous tissue, composed of
many cell types. Thus, this study cannot link changes to speciﬁc
cell types in the DRG. In situ hybridization and/or immunohisto-
chemical experiments are required to further clarify this point.
Thirdly, in an effort to minimize animal usage and reduce biologi-
cal variability, we employed a 2 cycle ampliﬁcation protocol to
generate the microarray targets. The 2 cycle ampliﬁcation protocol
produces reproducible results with high correlation between
ampliﬁed and non-ampliﬁed RNAs (Saghizadeh et al., 2003; Klur
et al., 2004; Li et al., 2005). However, RNA ampliﬁcation may cause
slight distortion (mainly decrease) of the expression ratios (Diboun
et al., 2006) and failure to detect transcripts from the low intensity
range (van Haaften et al., 2006). Therefore, our data might suffer
from a slight increase in false negative results. This offers an expla-
nation as to why differential expression for ATF3, Galanin, CCL2
and GFAP were detected by immunohistochemistry (Wallace
et al., 2007b) but not by microarrays for the gp120 + ddC model
(which exhibits subtle gene changes). Finally, we used a model of
HIV-related neuropathy that includes two insults to the nervous
system, gp120 and ddC, instead of the insults been applied individ-
ually. This model is clinically relevant since the decision to com-
mence antiretroviral therapy is taken at a time when there is a
high viral load and therefore circulating gp120 levels are high, with
patients being simultaneously exposed to the double neurotoxic
insults of gp120 and antiretroviral drugs (Gazzard et al., 2006;
Wallace et al., 2007b). However, whereas our model reﬂects the
clinical situation, we cannot be certain whether it is gp120, ddC
or the combination which drives the gene changes seen.
Despite the potential limitations of this microarray study, we
identiﬁed several potential targets for mechanical hypersensitivity
maintenance. Thirty-nine genes/ESTs are differentially regulated in
the same direction in both of our models. Of these genes, NPY has
previously been suggested to contribute to nerve injury-induced
mechanical hyperalgesia (White, 1997; Ossipov et al., 2002; Int-
ondi et al., 2007). However, the majority of genes highlighted by
our experiment represent potential novel targets in pain process-
ing, two of which are discussed in more detail below.
Fig. 5. RT-PCR results for Npy, Pap/Reg2 and Vgf in SNT, gp120 + ddC and VZV
infected animals. Normalized expression levels for each gene are expressed as ratios
to cyclophilin. Data are expressed as means ± SD. *, (p < 0.05) indicates statistical
signiﬁcance between treated and sham groups of animals (Student’s t test).
gp120 VZV L5 SNT
sham treated sham treated sham treated
β-actin
Reg2
Fig. 6. Immunoblots showing the induction of REG2/PAP protein expression in DRG
from sham and SNT-, gp120 + ddC- and VZV-treated animals. The same membrane
was re-probed with an anti b-ACTIN antibody.
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models. VGF expression is induced by neurotrophins such as nerve
growth factor (NGF) and brain-derived neurotrophic factor (BDNF)
which are themselves important in the development, maintenance
and normal functioning of neurons in the nervous system (Levi
et al., 1985; Cho et al., 1989; Salton et al., 1991; Alder et al.,
2003). The majority of experimental work on VGF peptide has fo-
cused upon its role as an energy homeostasis regulator (Hahm
et al., 1999; Hahm et al., 2002; Watson et al., 2005; Bartolomucci
et al., 2006) whilst the precise mechanism of VGF action and its
role in pain requires further study. However, it is known that in
the PNS, VGF is expressed mainly in small to medium diameter
sensory neurons that project to the superﬁcial laminae of the
spinal cord (Ferri et al., 1992). VGF is a secreted polypeptide (Pos-
senti et al., 1989), and thus may potentially mediate neuronal com-
munication. Furthermore, another function of VGF is synaptic
strengthening associated with learning ,memory and anti-depres-
sant like behavioural effects (Alder et al., 2003; Thakker-Varia
et al., 2007; Hunsberger et al., 2007). VGF has also been shown
to be up-regulated in rat DRG at 2–28 days following axotomy
(Xiao et al., 2002; Costigan et al., 2002). Although, axotomized rats
do not develop mechanical hypersensitivity of the hind-paw due to
deafferentation, VGF is also implicated as an important target in
this model and clearly merits further investigation with regard to
its role in pain.
Pap/Reg2 was also signiﬁcantly up-regulated in both models.
Reg-2 is a macrophage chemoattractant that is dynamically ex-
pressed in rat sensory neurons after peripheral nerve injury (Ave-
rill et al., 2002; Namikawa et al., 2005; Namikawa et al., 2006) and
has been implicated in regeneration of motor and sensory neurons
(Livesey et al., 1997; Namikawa et al., 2006). This regenerative role
may account for the increase in SNT DRG as compared to the
gp120 + ddC model. However, although largely expressed by in-
jured neurons, Reg-2 has also been shown to be upregulated in
uninjured axons also (Averill et al., 2002), which may implicate a
non-regeneration associated role that may relate to mechanisms
of hypersensitivity. The role of Reg-2 in pain is yet to be deter-
mined and our results suggest that this may be a good candidate
to investigate for such properties.
This study has identiﬁed 39 potential mechanical hypersensitiv-
ity related genes/ESTs associated with the development of
mechanical hypersensitivity and thigmotaxis following damage
to the peripheral nervous system. Functional studies are now re-
quired to verify that the products of these genes are indeed in-
volved in the generation and/or maintenance of neuropathic
pain. Some of these genes may become targets for developing no-
vel therapeutics to treat neuropathic pain at the level of the pri-
mary sensory neurone; where there is probably the most
favourable prospect of developing analgesic drugs with a favour-
able therapeutic index in respect of CNS mediated adverse effects.
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